To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Interscalene infusion of ropivacaine for pain relief following arthroscopic acromioplasty

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
May 2013

Interscalene infusion of ropivacaine for pain relief following arthroscopic acromioplasty

Vol: 2| Issue: 4| Number:117| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Interscalene versus subacromial continuous infusion of ropivacaine after arthroscopic acromioplasty: A randomized controlled trial

J Shoulder Elbow Surg. 2009 Jul-Aug;18(4):566-72. Epub 2009 Feb 11.

Contributing Authors:
T Winkler AJ Suda RV Dumitrescu O Pinggera G Weber G Loho B Schneider C Wurnig

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

40 patients undergoing arthroscopic acromioplasty were randomized to receive continuous catheter infusion with ropivacaine through either an interscalene or subacromial catheter site. This study evaluated the efficacy of two different catheter sites for local anesthetic infusion to provide pain relief following arthroscopic acromioplastty. The results from this study indicated that use of an inter...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue